AI Engines For more Details: Perplexity Kagi Labs You
Bacterial Infections: Cefmetazole is effective against a wide range of Gram-positive and Gram-negative bacteria. It is commonly used to treat infections caused by organisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterobacter species, and Streptococcus species.
Intra-abdominal Infections: Cefmetazole is particularly useful in the treatment of intra-abdominal infections, including peritonitis and abscesses. It can penetrate well into abdominal tissues and effectively target the causative bacteria.
Urinary Tract Infections: Cefmetazole is also used to treat urinary tract infections (UTIs), including cystitis and pyelonephritis. It can eradicate bacteria commonly responsible for UTIs, such as Escherichia coli and Klebsiella pneumoniae.
Respiratory Tract Infections: In some cases, cefmetazole may be prescribed to treat respiratory tract infections, including pneumonia and bronchitis, particularly when caused by susceptible bacteria.
Skin and Soft Tissue Infections: Cefmetazole can be used to treat certain skin and soft tissue infections caused by susceptible bacteria. It may be prescribed for cellulitis, wound infections, and other similar conditions.
Surgical Prophylaxis: Cefmetazole is often used prophylactically to prevent surgical site infections in procedures such as colorectal surgery, gynecological surgery, and abdominal surgery.
Dosage and Administration: Cefmetazole is typically administered intravenously, either as a bolus injection or by continuous infusion. The dosage and duration of treatment depend on the type and severity of the infection, as well as the patient's age, weight, and renal function.
Adverse Effects: Common side effects of cefmetazole may include gastrointestinal symptoms such as diarrhea, nausea, vomiting, and abdominal pain. Allergic reactions, including rash, itching, and swelling, can occur, although they are relatively rare.
Drug Interactions: Cefmetazole may interact with other medications, particularly those that affect renal function or interfere with the absorption of antibiotics. It is essential to review the patient's medication history and potential drug interactions before prescribing cefmetazole.
Resistance: Bacterial resistance to cefmetazole is a concern, particularly in regions where antibiotic use is widespread. Resistance can develop due to overuse or misuse of antibiotics, making treatment less effective over time.
Pediatric and Geriatric Use: Cefmetazole can be used in pediatric and geriatric populations, although dosage adjustments may be necessary based on age, weight, and renal function.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.5 | -0.5 | |
ADHD | 6.7 | 1 | 5.7 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.3 | 2.33 |
Allergic Rhinitis (Hay Fever) | 2.6 | 2.5 | 0.04 |
Allergies | 7.1 | 4.5 | 0.58 |
Allergy to milk products | 2.4 | 1.3 | 0.85 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 5.8 | 8.9 | -0.53 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 6 | 2.5 | 1.4 |
Ankylosing spondylitis | 6.5 | 2.9 | 1.24 |
Anorexia Nervosa | 0.3 | 3.4 | -10.33 |
Antiphospholipid syndrome (APS) | 2.5 | 2.5 | |
Asthma | 2 | 2.3 | -0.15 |
Atherosclerosis | 2 | 3.5 | -0.75 |
Atrial fibrillation | 5.1 | 2.6 | 0.96 |
Autism | 15.8 | 14.6 | 0.08 |
Barrett esophagus cancer | 1 | 0.5 | 1 |
benign prostatic hyperplasia | 0.5 | 0.5 | |
Bipolar Disorder | 1.6 | 2.5 | -0.56 |
Brain Trauma | 1 | 0.9 | 0.11 |
Carcinoma | 5.1 | 3.6 | 0.42 |
Celiac Disease | 3.9 | 5.6 | -0.44 |
Cerebral Palsy | 2.5 | 1.9 | 0.32 |
Chronic Fatigue Syndrome | 8 | 8.9 | -0.11 |
Chronic Kidney Disease | 3.6 | 3 | 0.2 |
Chronic Lyme | 0.9 | -0.9 | |
Chronic Obstructive Pulmonary Disease (COPD) | 3.5 | 1.5 | 1.33 |
Chronic Urticaria (Hives) | 3 | 3 | 0 |
Coagulation / Micro clot triggering bacteria | 2.3 | 2 | 0.15 |
Colorectal Cancer | 7.6 | 1.5 | 4.07 |
Constipation | 2.4 | 1 | 1.4 |
Coronary artery disease | 2.5 | 1.5 | 0.67 |
COVID-19 | 16 | 20.9 | -0.31 |
Crohn's Disease | 12.6 | 9.1 | 0.38 |
cystic fibrosis | 1.5 | 1.4 | 0.07 |
deep vein thrombosis | 1.5 | 1.5 | 0 |
Depression | 15 | 12 | 0.25 |
Dermatomyositis | 0.5 | 0.5 | 0 |
Eczema | 2 | 3.5 | -0.75 |
Endometriosis | 4.6 | 2 | 1.3 |
Eosinophilic Esophagitis | 0.5 | 0.5 | 0 |
Epilepsy | 4.8 | 3.1 | 0.55 |
Fibromyalgia | 3.3 | 4.4 | -0.33 |
Functional constipation / chronic idiopathic constipation | 8.5 | 6 | 0.42 |
gallstone disease (gsd) | 3.3 | 1.5 | 1.2 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 3 | 1.5 | 1 |
Generalized anxiety disorder | 3.5 | 2.8 | 0.25 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.5 | -0.5 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.6 | 2 | -0.25 |
Halitosis | 1.4 | 0.5 | 1.8 |
Hashimoto's thyroiditis | 3.8 | 0.9 | 3.22 |
Hidradenitis Suppurativa | 1 | 0.5 | 1 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 5.3 | 1.5 | 2.53 |
hypercholesterolemia (High Cholesterol) | 1 | 1 | 0 |
hyperglycemia | 0.5 | 3.1 | -5.2 |
Hyperlipidemia (High Blood Fats) | 1.5 | 0.5 | 2 |
hypersomnia | 0.5 | -0.5 | |
hypertension (High Blood Pressure | 3.6 | 7.3 | -1.03 |
Hypothyroidism | 2 | -2 | |
Hypoxia | 1.1 | 1.1 | |
IgA nephropathy (IgAN) | 5.4 | -5.4 | |
Inflammatory Bowel Disease | 7.8 | 13.8 | -0.77 |
Insomnia | 1.4 | 1.4 | 0 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 1.6 | 0.5 | 2.2 |
Irritable Bowel Syndrome | 6 | 6 | 0 |
Liver Cirrhosis | 7.1 | 4.8 | 0.48 |
Long COVID | 12.2 | 12.1 | 0.01 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 1.1 | 2.5 | -1.27 |
ME/CFS with IBS | 2 | 3.9 | -0.95 |
ME/CFS without IBS | 3.5 | 3.4 | 0.03 |
Menopause | 2.4 | 2.4 | |
Metabolic Syndrome | 12.2 | 13.4 | -0.1 |
Mood Disorders | 19.5 | 12.5 | 0.56 |
multiple chemical sensitivity [MCS] | 2.5 | 0.5 | 4 |
Multiple Sclerosis | 9.2 | 8.6 | 0.07 |
Multiple system atrophy (MSA) | 3.5 | 1.5 | 1.33 |
Neuropathy (all types) | 1.5 | 0.5 | 2 |
neuropsychiatric disorders (PANDAS, PANS) | 1.5 | 1.5 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4 | 8.3 | -1.08 |
NonCeliac Gluten Sensitivity | 0.5 | -0.5 | |
Obesity | 12.7 | 7.4 | 0.72 |
obsessive-compulsive disorder | 9.7 | 7.3 | 0.33 |
Osteoarthritis | 3.8 | 0.5 | 6.6 |
Osteoporosis | 2.9 | 1.9 | 0.53 |
pancreatic cancer | 1 | 1 | |
Parkinson's Disease | 5.2 | 7 | -0.35 |
Polycystic ovary syndrome | 3.6 | 3.5 | 0.03 |
Postural orthostatic tachycardia syndrome | 0.5 | 1 | -1 |
Premenstrual dysphoric disorder | 1.5 | 0.3 | 4 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 7.5 | 4.6 | 0.63 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 10.6 | 5.9 | 0.8 |
Rosacea | 2 | 1 | 1 |
Schizophrenia | 10.6 | 3 | 2.53 |
scoliosis | 0.5 | 1.5 | -2 |
Sjögren syndrome | 4.8 | 4.6 | 0.04 |
Sleep Apnea | 2.5 | 2.4 | 0.04 |
Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 1 | 1 |
Stress / posttraumatic stress disorder | 4.6 | 4.3 | 0.07 |
Systemic Lupus Erythematosus | 6.6 | 3 | 1.2 |
Tic Disorder | 2 | 2.5 | -0.25 |
Tourette syndrome | 0.5 | 0.4 | 0.25 |
Type 1 Diabetes | 5.3 | 4 | 0.32 |
Type 2 Diabetes | 12.7 | 10.9 | 0.17 |
Ulcerative colitis | 4.5 | 8 | -0.78 |
Unhealthy Ageing | 9.5 | 3.5 | 1.71 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.